On June 27, 2024, William Peters, the Chief Financial Officer, Executive Vice President, and Treasurer of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH), sold 3,596 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 94,103 shares of the company. Warning! GuruFocus has detected 5 Warning Signs with AMPH. Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) is a biopharmaceutical company that focuses on the development, manufacturing, and marketing of generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company is involved in the development and sale of insulin active pharmaceutical ingredient products. Over the past year, William Peters has sold a total of 141,725 shares and has not made any purchases of the company's stock. In the same period, there have been 24 insider sells and no insider buys at Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). On the day of the sale, shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) were trading at $40.93. This pricing gives the company a market cap of approximately $1.96 billion. The price-earnings ratio of the stock stands at 13.84, which is below both the industry median of 22.18 and the companys historical median. According to the GF Value, the intrinsic value of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) is estimated at $46.22 per share, suggesting that the stock is modestly undervalued with a price-to-GF-Value ratio of 0.89. The GF Value is calculated based on historical trading multiples like the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the companys past performance and expected future business outcomes. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus.
Insider Sale: CFO, EVP & Treasurer William Peters Sells Shares of Amphastar Pharmaceuticals ...
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...